ArticleInternational journal of clinical and experimental pathology2017
DKK1 maintained cancer stem-like properties of esophageal carcinoma cells via ALDH1A1/SOX2 axis.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Dickkopf-1 promotes tumor progression of gefitinib- resistant non-small cell lung cancer through cancer cell-fibroblast interactions.Experimental hematology & oncology · 2025Article
- Knockdown of WISP1/DKK1 restrains phenotypic plasticity in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition and stemness.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- A NovelClinical Medicine Insights. Oncology · 2024Article
- Morpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms.British journal of cancer · 2022Article
- RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis.The Journal of clinical investigation · 2022Article
- ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism.Frontiers in oncology · 2022Review
- Pan-Cancer Analyses Reveal Oncogenic and Immunological Role of Dickkopf-1 (DKK1).Frontiers in genetics · 2021Article
- Dickkopf-1: A Promising Target for Cancer Immunotherapy.Frontiers in immunology · 2021Review
- Review
- Aldehyde Dehydrogenase-1A1 (ALDH1A1): The Novel Regulator of Chemoresistance in Pancreatic Cancer Cells.Cancer control : journal of the Moffitt Cancer CenterReview
- Long Non-coding RNAs WithCancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dickkopf-1 (DKK1) has been reported as a key regulator in the progression of esophageal carcinoma (EC). Aldehyde dehydrogenase 1A1 (ALDH1A1) possesses stem-like properties and predicts patient outcome in several cancers. However, whether DKK1 regulates cancer stem-like properties of EC cells through modulating ALDH1A1 activity remains unclear. In this study, we found that DKK1 knockdown significantly reduced cell proliferation, colony formation and CK18 expression. Additionally, knockdown of DKK1 also decreased the expression of ALDH1A1 involved in a c-Jun-dependent manner through a pathway consisting of p38/JNK/c-Jun pathway. Furthermore, the downregulation of ALDH1A1 gene expression in Eca109 resulted in decreased expression of cancer stem cell-associated markers SOX2, Bmi1 and vimentin. Therefore, our results demonstrated that DKK1 maintained cancer stem-like properties of EC cells via ALDH1A1/SOX2 axis. DKK1 may act as a therapeutic target for the treatment of EC.
Indexed as
Identifiers
31966823PMC6965918W3016126424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.